HS Code:
4-[(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile, commonly known as Crisaborole, is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema). Classified under HS Code 2934.99.30, it falls within the category of other heterocyclic compounds. Crisaborole works as a phosphodiesterase 4 (PDE4) inhibitor, reducing inflammation in affected skin areas. This product is primarily traded as a pharmaceutical active ingredient or in finished dosage forms, with significant interest in dermatological applications globally.
Total Trade Volume
Approximately $150 million USD
Data from 2022
Source
Estimated based on data from UN Comtrade, ITC Trade Map, and industry reports
$80 million USD
53.3% of total trade of total trade
Increasing
$25 million USD
16.7% of total trade of total trade
Stable
$15 million USD
10.0% of total trade of total trade
Increasing
$10 million USD
6.7% of total trade of total trade
Increasing
$8 million USD
5.3% of total trade of total trade
Stable
Average Rate
5.5% ad valorem
Highest Rate
8.0% (applied by certain developing countries)
Lowest Rate
0% (under free trade agreements or for WTO members with pharmaceutical exemptions)
Rising demand for nonsteroidal anti-inflammatory treatments
Increased production and trade of Crisaborole as a safer alternative to corticosteroids for eczema treatment, especially in pediatric populations
2021-2023
Growth in generic formulations
Post-patent expiration in key markets, generic versions of Crisaborole are driving down costs and increasing accessibility, boosting trade volumes
2022-2023
Expansion of dermatological markets in Asia-Pacific
Growing awareness of skin conditions and increasing healthcare spending in countries like India and China are driving imports of Crisaborole-based products
2020-2023
The U.S. Food and Drug Administration approved multiple generic versions of Crisaborole ointment, enhancing market competition and accessibility.
October 2022
Significant reduction in prices in the U.S. market, leading to increased trade volumes and imports from API manufacturers in India and China.
The European Medicines Agency (EMA) issued updated guidelines for the approval of PDE4 inhibitors, including Crisaborole, streamlining market entry.
March 2023
Facilitated exports to EU countries, with Germany and France seeing higher import volumes of finished formulations.
New trade agreements between the U.S. and India reduced tariffs on pharmaceutical APIs, including Crisaborole intermediates.
June 2023
Boosted exports from India to the U.S., strengthening India's position as a key supplier of raw materials for Crisaborole production.